Pronethalol
Pronethalol
Pronethalol (/proʊˈnɛθəlɒl/) is a non-selective beta blocker that was the first of its kind to be developed. It was discovered by Sir James Black in the 1960s.
Etymology
The term "Pronethalol" is derived from the chemical structure of the drug, which is a propanolamine derivative. The prefix "pro-" refers to the propyl group in its structure, "-ne-" refers to its naphthyl group, and "-th-" refers to its thiadiazole group. The suffix "-ol" is commonly used in the names of alcohols and indicates the presence of a hydroxyl (-OH) group.
History
Pronethalol was developed by Sir James Black and his team at the ICI Pharmaceuticals Division in the United Kingdom. It was the first beta blocker to be discovered, but it was not marketed due to its potential to cause thymomas (tumors of the thymus gland) in laboratory animals.
Pharmacology
As a non-selective beta blocker, Pronethalol works by blocking the action of epinephrine (adrenaline) and norepinephrine (noradrenaline) on the beta receptors of the heart and blood vessels. This reduces the heart rate, decreases blood pressure, and helps to prevent angina (chest pain) caused by reduced blood flow to the heart.
Related Terms
External links
- Medical encyclopedia article on Pronethalol
- Wikipedia's article - Pronethalol
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski